VERTEX PHARMACEUTICALS INC (VRTX) 321.32 +3.74 (+1.18%)
321.32 +3.74 (+1.18%)
US92532F1003 - Common Stock - After market: 321.32 0 (0%)
Fundamental Rating
Overall VRTX gets a fundamental rating of 6 out of 10. We evaluated VRTX against 635 industry peers in the Biotechnology industry. VRTX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. VRTX is quite expensive at the moment. It does show a decent growth rate.
Profitability
Profitability Rating
VRTX's Return On Assets of 19.59% is amongst the best returns of the industry. VRTX outperforms 97% of its industry peers. The industry average Return On Assets is -44.81%.
VRTX has a Profit Margin of 37.62%. This is amongst the best returns in the industry. The industry average is -464.10%. VRTX outperforms 94% of its industry peers.
VRTX has a very good Piotroski-F score of 8.00. This indicates a great health and profitability for VRTX.
VRTX has a Return On Equity of 25.12%. This is comparable to the industry average of 22.42%.
VS Industry
ROA (19.59%) VS Industry: 97% outperformed.
-3,944.82
115.38
ROE (25.12%) VS Industry: 57% outperformed.
0.21
217.75
Profit Margin (37.62%) VS Industry: 94% outperformed.
-1,173,705.71
34,743.00
Valuation
Valuation Rating
With a Price/Earnings Ratio of 22.16, VRTX is valued on the expensive side.
The Forward Price/Earnings Ratio of 20.37 indicates a rather expensive current valuation of VRTX.
When comparing the current price to the book value of VRTX, we can conclude it is valued correctly. It is trading at 6.33 times its book value.
Compared to an average industry Price/Earning Ratio of 14.22, VRTX is valued slightly more expensive.
The high PEG Ratio, which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
When comparing the price book ratio of VRTX to the average industry price book ratio of 1.69, VRTX is valued more expensive than its industry peers. 89% of the companies listed in the same industry are valued cheaper.
Compared to an average industry Enterprise Value to EBITDA ratio of 1.08, VRTX is valued more expensive than its industry peers. 95% of the companies listed in the same industry are valued cheaper.
VS Industry
Price/Earnings (22.16) VS Industry: 29% outperformed.
420.33
0.13
Price/Book (6.33) VS Industry: 11% outperformed.
138.52
0.09
Enterprise Value/ EBITDA (16.84) VS Industry: 5% outperformed.
3,199.01
0.01
Growth
Growth Rating
The Earnings Per Share has grown by an nice 19.24% over the past year.
The Earnings Per Share has been growing by 73.01% on average over the past 5 years. This is a very strong growth
VRTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.03%.
The Revenue has been growing by 34.79% on average over the past 5 years. This is a very strong growth!
VRTX is expected to show a small growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 7.44% yearly.
The Revenue is expected to grow by 7.02% on average over the next 5 years.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | 73.01% | 47.11% | 19.24% | 11.11% | 10.08% | 8.39% | 7.44% |
| Revenue | 34.79% | 35.46% | 22.03% | 18.51% | 12.75% | 10.86% | 7.02% |
Health
Health Rating
A Current Ratio of 4.70 indicates that VRTX has no problem at all paying its short term obligations.
VRTX has a Quick Ratio of 4.55. This indicates that VRTX is financially healthy and has no problem in meeting its short term obligations.
An Altman-Z score of 15.98 indicates that VRTX is not in any danger for bankruptcy at the moment.
VRTX has one of the better Altman-Z scores in its industry. It is much better than the industry average of -0.65. VRTX has a better score than 92% of its industry peers.
VRTX has a very good Piotroski-F score of 8.00. This indicates a great health and profitability for VRTX.
When comparing the Debt to Equity Ratio of VRTX to the average industry Debt to Equity Ratio of 0.00, VRTX required more debt to finance its operations than its industry peers.
We won't put much weight on the industry comparison as VRTX has a very low Debt to Equity (0.03).
We won't put much weight on the industry comparison as VRTX has a very low Debt to Equity (0.03).
Compared to an average industry Current Ratio of 6.11, VRTX is worse placed to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 6.02, VRTX is worse placed to pay its short term obligations than its industry peers.
VS Industry
Debt/Equity (0.03) VS Industry: 29% outperformed.
15.37
0.00
Quick Ratio (4.55) VS Industry: 38% outperformed.
0.02
84.53
Current Ratio (4.7) VS Industry: 39% outperformed.
0.02
85.09
Altman-Z (15.98) VS Industry: 92% outperformed.
-1,822.12
441.73
Dividend
Dividend Rating
No dividends for VRTX!.
VERTEX PHARMACEUTICALS INC321.32
NASDAQ:VRTX (12/8/2022, 3:04:34 PM)+3.74 (+1.18%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 10-27 2022-10-27/amc | Earnings (Next) | 01-24 2023-01-24 |
| Ins Owners | 0.18% | Inst Owners | 92.51% |
| Market Cap | 82.48B | Analysts | 78.29 |
| PE | 22.16 | Fwd PE | 20.37 |
| PEG (NY) | 1.99 | PEG (5Y) | 0.3 |
| P/S | 9.48 | P/B | 6.33 |
| EV/EBITDA | 16.84 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS 1Y | 19.24% | EPS 3Y | 47.11% |
| EPS 5Y | 73.01% | EPS growth Q2Q | 12.64% |
| EPS Next Y | 11.11% | EPS Next 2Y | 10.08% |
| EPS Next 3Y | 8.39% | EPS Next 5Y | 7.44% |
| Revenue growth 1Y | 22.03% | Revenue growth 3Y | 35.46% |
| Revenue growth 5Y | 34.79% | Revenue growth Q2Q | 17.65% |
| Revenue Next Year | 18.51% | Revenue Next 2Y | 12.75% |
| Revenue Next 3Y | 10.86% | Revenue Next 5Y | 7.02% |
| Current Ratio | 4.7 | Quick Ratio | 4.55 |
| Altman-Z | 15.98 | F-Score | 8 |
| Debt/Equity | 0.03 | WACC | 8.97% |
| ROIC/WACC | 15.15 | ||
| ROA | 19.59% | ROE | 25.12% |
| ROICexgc | 135.89% | ROIC | 25.52% |
| PM | 37.62% | OM | 47.87% |
| Asset Turnover | 0.52 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA